SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " mize " 399 found 🔀 AI-powered Shuffle
Denver Guard Epitomizes Broncos Toughness, Resilience
The Denver Broncos have some tough players, but no one embodies their resilience like guard Ben Powers.
LZ Sees Surprising Result in Search for Dark Matter
Key Takeaways Dark matter is the mysterious substance that accounts for the vast majority of matter in our universe. LUX-ZEPLIN (LZ) is a world-leading dark matter detector and specializes in searching for WIMPs, or weakly interacting massive particles. A new LZ study found one particle interaction that is difficult to explain with known background processes and could potentially have been caused by a WIMP. LZ continues to run to see if additional data strengthens or weakens the hint of a dark matter interaction. For the better part of a century, people have been trying to understand dark matter. This invisible substance makes up roughly 85% of the mass in the universe but has never been directly detected. Determining exactly what it is remains one of the biggest questions about our world. Now, a new analysis from the LUX-ZEPLIN (LZ) experiment has recorded a single particle interaction that researchers have great difficulty explaining with known background signals from normal matter. The result does not yet meet the statistical threshold required to claim a discovery, but is the most compelling hint of dark matter reported by the experiment to date. LZ is an international collaboration of 250 scientists and engineers from 39 institutions. The detector is managed by the U.S. Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) and operates nearly one mile below ground at the Sanford Underground Research Facility (SURF) in South Dakota. The experiment uses 10 tonnes of ultrapure liquid xenon to search for dark matter and is optimized to look for WIMPs, or weakly interacting massive particles. The results were presented in a scientific talk at the 2026 TeV Particle Astrophysics conference in Japan. The paper will be released on the online repository arXiv and submitted to the journal Physical Review Letters. “We’re very intrigued to see this event in the data, in the region where we expect dark matter to show up and the competing backgrounds are very low,” said Rick Gaitskell, a professor at Brown University and the spokesperson for LZ. “With only one event, we don’t want to get ahead of ourselves. We are not claiming to have seen dark matter. But we have seen something interesting that we want to share with the scientific community for their input.” The LZ collaboration studies experimental data in batches. In the new result, researchers analyzed 220 live days of data collected between March 2023 and April 2024. The collaboration had previously searched this dataset for faint signals from the simplest kinds of WIMP interactions. The new analysis searched for a broader range of possible WIMP interactions that could deposit more energy in the detector. LZ is particularly sensitive to such signals while also minimizing false positives. “This was a detailed study in a region we hadn’t explored within this dataset, and we spent months of additional effort to understand all the possible causes of background events,” said Sam Eriksen, a senior research associate at the University of Bristol in the U.K. and lead author of the study. “We understand our detector and the backgrounds so well that even a single outstanding event, like the one we found, is important. We expect dark matter events to be extremely rare, so only a handful could mark the first detection of WIMP dark matter.” If the anomalous event was caused by dark matter, the WIMP that generated it would likely have a mass of at least 200 GeV/c2 (gigaelectronvolts), or more than 200 times the mass of a proton. It would also suggest a specific type of interaction between WIMPs and ordinary matter beyond the simplest model. The LZ results have not reached “5-sigma” significance, the statistical threshold considered a discovery in physics. The new analysis is 2.6 sigma, meaning there is approximately a 0.5% chance that the event could be explained by known backgrounds. With additional data, researchers can test whether the finding continues to grow in significance or fades away. LZ has already accumulated the world’s largest dark matter dataset and will continue to accrue WIMP search data at SURF, substantially improving their search statistics. LZ searches for dark matter by looking for signature flashes of light from energy deposited in the detector. The collaboration leverages multiple methods to prevent or account for particle interactions caused by normal matter. This includes the mile of rock that shields the detector from cosmic rays from space, a water tank and outer detectors that protect the central detector from background neutrons, and a suite of computational tools that disentangle particle interactions and reject dark matter mimics. “Outlier events in the data are not unexpected, but they usually stand out as a background of some kind when you look at them deeper,” said Aaron Manalaysay, a physicist at Berkeley Lab and the chair of LZ’s Institutional Board. “This is the first example in any experiment I’ve worked on of an outlier that appears valid in every way. Of course, we’re still twisting our brains trying to think if there’s a rare background mechanism we could’ve missed, but it’s thrilling to wonder if this could be the first hint of a dark-matter observation.” LZ is supported by the U.S. Department of Energy, Office of Science, Office of High Energy and Nuclear Physics, and the National Energy Research Scientific Computing Center, a DOE Office of Science user facility. LZ is also supported by the Science & Technology Facilities Council of the United Kingdom; the Portuguese Foundation for Science and Technology; the Swiss National Science Foundation; the Australian Research Council Centre of Excellence for Dark Matter Particle Physics; and the Institute for Basic Science, Korea. Thirty-nine institutions of higher education and advanced research provided support to LZ. The LZ collaboration acknowledges the assistance of the Sanford Underground Research Facility. ### Lawrence Berkeley National Laboratory (Berkeley Lab) is committed to groundbreaking research focused on discovery science and solutions for abundant and reliable energy supplies. The lab’s expertise spans materials, chemistry, physics, biology, earth and environmental science, mathematics, and computing. Researchers from around the world rely on the lab’s world-class scientific facilities for their own pioneering research. Founded in 1931 on the belief that the biggest problems are best addressed by teams, Berkeley Lab and its scientists have been recognized with 17 Nobel Prizes. Berkeley Lab is a multiprogram national laboratory managed by the University of California for the U.S. Department of Energy’s Office of Science. DOE’s Office of Science is the single largest supporter of basic research in the physical sciences in the United States, and is working to address some of the most pressing challenges of our time. For more information, please visit energy.gov/science.
Seoul National University of Science and Technology develops AI framework to test and improve vision-system robustness
A new artificial intelligence (AI)-based system shows how natural damage to traffic signs can mislead deep neural network (DNN)-based vision systems. The framework, AdvWT, uses a generative model to learn realistic damage patterns and then optimize them to trigger misclassification. Tests across multiple AI architectures showed strong attack success, transferability and physical-world robustness. The approach can identify vulnerabilities and improve AI generalization to real-world damage.
Scientists Are Using AI And Viruses To Help Defeat Superbugs
Deep learning models can help scientists build customized phages.
Scientists Are Using AI And Viruses To Help Defeat Superbugs
Deep learning models can help scientists build customized phages.
Colorado Sues EarnIn For “Immoral, Unethical, Oppressive and Unscrupulous” Business Practices
Hey all, Jason here. When this hits your inbox, I should be en route to the airport — not to go anywhere myself, just to pick up my better half. I must admit, it’s been strange to be home alone (well, with two dogs) for two weeks! Really lets me “optimize” to spending more time on reading/writing/working, whether that’s healthy or not! Looking forward to getting back into a (somewhat) more balance routine. Subscribe or Support by Upgrading Compare Notes With the People Who Built Modern Fintech Partner content: Remitly CEO Sebastian Gunningham. Increase founder Darragh Buckley. Linda Du, Co-founder & President at Valon. They’ll unpack the decisions behind building and scaling major financial products: what they got right, what broke, what they would do differently, and how AI and new infrastructure are changing the operator playbook. Most events tell you where fintech is going. NerdCon puts the people who built the present in the room and asks them what comes next. Expect an operator-led conversation grounded in real products, real trade-offs and lessons earned the hard way. Fintech Business Weekly readers save 20% on Regular tickets with code FBW20 before standard pricing ends September 11. Meet the Builders Things To Know & Other Good Reads Advent and Stripe Abandon $50 Billion Pursuit of PayPal (Bloomberg) Trump Family’s New Crypto Bank Is Backed by Abu Dhabi Sheikh (Wall Street Journal) The multiplying risks of financing data centres (FT) Let the Bond Market Speak (Wall Street Journal) Did we waste a crisis? Modest proposals to reform deposit insurance. (Fintech Takes Banking) Untangling Guggenheim: How Private Credit Built Its Own Universe (Net Interest) The Hater’s Guide To Circular Financing — Part One (Ed Zitron) Fiat Ventures Rebrands to FGV Capital, Announces $35M Oversubscribed Fund II (BusinessWire) Socure Announces Strategic Growth Investment at $5.2B Valuation and Acquires Agentic Operations Platform Fravity (Socure) Listen: When Consumer Protection Disclosures Work Too Well (Consumer Finance Monitor Podcast) Colorado Sues EarnIn For “Immoral, Unethical, Oppressive and Unscrupulous” Business Practices When Andreessen Horowitz led EarnIn’s $39 million Series B in 2017, Alex Rampell, a partner at the storied venture capital firm, described EarnIn’s small-dollar advance product as “free,” relying on “entirely on voluntary contributions instead of fees.” Rampell favorably compared EarnIn’s approach to typical payday loans, writing, “Payday loans historically have had the potential to be a slippery slope for consumers into financial distress: opaque systems and steep fees that are hard to repay and set individuals back further than where they started. For many Americans living paycheck to paycheck, that kind of slide into debt can be extremely difficult to recover from.” But EarnIn’s product — which, the company says, isn’t a “loan,” legally speaking — ends up being anything but free for most users. While it is technically possible to take a no-fee advance from the company, most users incur “Lightning Speed” (instant funding) fees and/or ostensibly optional tips that combined can equate to annualized percent rates that can reach over 1,000%. With an average term of 9.77 days, even fees and tips that are small on an absolute dollar basis are equivalent to high APRs on an annualized basis. A lawsuit filed last week by Colorado Attorney General Phil Weiser against EarnIn describes the company and its product and business practices quite differently than Andreessen’s Rampell; “EarnIn’s business practices are unfair because they are immoral, unethical, oppressive and unscrupulous,” the complaint, filed in District Court in Denver, Colorado, says. EarnIn’s marquee product, Cash Out, isn’t a loan, the company says, as Cash Out is not “[f]orward [l]ooking” because “[t]he money is transferred based on earnings to date,” does not carry a mandatory fee to access funds, and is “non-recourse,” meaning EarnIn cannot pursue recovery from users who don’t repay advanced funds. EarnIn is sometimes referred to as an “Earned Wage Advance” service. Though, unlike some others in the broader category, EarnIn does not integrate with employers’ payroll or time and attendance systems. Rather, EarnIn attempts to verify a user’s income and employment, by examining direct deposit transaction data in their linked external bank account, by using GPS location and Bluetooth data to estimate a user’s time spent at work, if they work in a fixed location, and/or by having a user provided a work email address. While repayment is theoretically optional, as EarnIn would have no recourse, such as reporting non-payment to the credit bureaus or a collections agency, this is anything but clear to users of the EarnIn app, Colorado’s complaint argues. During the process of taking a Cash Out, users must agree to a preauthorized debit of the amount advanced, plus any expedited funding fee and/or tips. Though users technically can revoke this ACH authorization, the fact that they have this right isn’t presented to users during the Cash Out process, but rather is included in linked terms and conditions few users are likely to actually read. And users who do wish to revoke their ACH authorization must do so three or more days before the scheduled transaction date by emailing EarnIn’s customer support. Similarly, EarnIn’s marketing claims that it carries “no interest” and “no mandatory fees” is technically true, but is not the reality for many of the app’s users, the Colorado complaint argues. Further, EarnIn has extensively marketed to users the ability to “access your pay today,” to get “instant” funds, and to get funds “the same day you work” — when, in reality, this speed of access was only possible by paying the additional, undisclosed Lightning Speed fee. The Colorado complaint highlights this contradiction specifically, noting: EarnIn tells consumers that they can ‘Make any day payday with EarnIn’ and that there no ‘hidden’ or ‘mandatory fees.’ For a consumer to access their pay on the same day requested, they would have to pay the Lightning Speed fee. In the fine print of the advertisement EarnIn discloses that ‘[f]ees apply to use Lightning Speed,’ a direct contradiction to the larger text of the advertisement, and a fact that would not be immediately understood by a consumer as ‘Lightning Speed’ is not defined nor explained. Like other small-dollar lending services, rather than explicitly charge interest, EarnIn collects a markup on the optional Lighting Speed fee, which, given the nature of the transactions, many users opt for, as well as offering users the option to leave “tips.” EarnIn leverages either Real-Time Payments (RTP) rails or push-to-card via debit rails if a user opts for the optional Lightning Speed. But while these capabilities cost EarnIn, on average, $0.075 or $0.20 per transaction, respectively, EarnIn charges users significantly more. Initially, EarnIn charged as little as $1.99 for Cash Outs up to $24. But EarnIn has hiked these fees multiple times, and now charges $4.99 for Cash Outs up to $75 and $6.99 for those over $75. According to the Colorado complaint, EarnIn leverages “dark patterns” to manipulate users and to make it more difficult to avoid tipping. Examples of these “road blocks” highlighted in the complaint include: As of 2023, in the EarnIn app, a consumer attempting to get a loan under the default settings had to make at least eighteen separate taps to complete the transaction and reduce the tip to $0. There is an alternative method to leave a $0 tip, via the “Custom tip” feature, but EarnIn made this option difficult to access by visually deemphasizing it and positioning it near devices’ “home” button. Using language and imagery such as “Tip to pay it forward,” “Your generosity supports the service + helps,” “Your tips make a difference,” and “[t]he APR for this cash out is 0%. Your tips help support us.” While Lightning Speed and tipping are, in theory, both optional, in practice, users nearly always ended up paying something. According to the Colorado suit, users were charged either a tip or an expedite fee for more than 92% of transactions, with an average APR of nearly 388%. And, although the advances are “non-recourse,” EarnIn successfully collects on nearly all transactions — 99.18%, according to the complaint, which, Colorado argues, “demonstrat[es] that EarnIn’s advances function as high cost loans, not voluntary payments.” The share of EarnIn users incurring fees — despite the product being marketed as 0% APR — is hard to reconcile with Andreessen investor Rampell’s favorable description of EarnIn vs. “opaque systems and steep fees” associated with payday loans, which, Rampell says, can be “extremely difficult” for borrowers to extricate themselves from. According to Colorado’s suit, EarnIn’s Cash Out product “trapped many consumers in extreme cycles of high-cost reborrowing.” The suit gives an example of one consumer in the state, who took out a whopping 1,151 loans, paying a total of $4,038.50 in Lightning Speed expedited funding fees on loans that averaged the equivalent of 1,421% APR. Another Colorado user, the suit says, took out 1,033 loans, paying $8,561.22 in tips and fees at an average APR of 1,539% . These types of usage patterns demonstrate “the severe and repeated financial harm caused by EarnIn’s illegal lending model,” the Colorado complaint argues. In aggregate, from January 2023 through July 2025, EarnIn extended 3.1 million loans to 56,778 users in Colorado — an average of nearly 55 transactions per person during the time period. EarnIn lent more than $300 million and collected more than $16 million from Colorado users in Lightning Speed fees and in tips. Ultimately, the Colorado complaint argues that “EarnIn’s Cash Outs are loans under Colorado law, and EarnIn’s contention that its product is not a loan based on its disclaimer of any legal repayment obligation lacks any real-world significance given how the Cash Out transactions actually operate in practice.” Colorado further argues that “EarnIn was not working with companies here in providing consumers with funds but acted as a third-party lender and charged illegally high rates, used deceptive design strategies to extract some charges, and trapped consumers in repeat borrowing. Colorado will continue to stand up for consumers and hold companies accountable when they violate our credit laws or attempt to evade them through misleading practices.” Colorado’s suit alleges EarnIn assesses finance charge in excess of that permitted by Colorado law, that EarnIn failed to make legally required disclosures to Colorado borrowers, that EarnIn made supervised loans to consumers without obtaining the requisite license, that EarnIn violated the state’s Deferred Deposit Loan Act, that EarnIn engage in unfair and deceptive trade practices, and that EarnIn made false or misleading statements concerning price. The suit seeks a court order enjoining EarnIn from violating relevant Colorado laws, for EarnIn to refund amounts charged in excess of state law, fees, costs, and penalties, and other relief the court deems to be just. Fintech Business Weekly is made possible by the generous support of paying subscribers — bringing you independent analysis of banking, fintech, and crypto without fear or favor. You can support my work by becoming a paying subscriber if you aren’t already. Paying subscribers enjoy: access to the entire archive of nearly six years of newsletters extended versions of the weekly newsletter, with additional content and analysis and (for founding member tier) quarterly personal 1:1 fintech Q&A / strategy calls with me, tapping into my unparalleled knowledge of the intersection of banking and fintech and experience working in the sector, including helping to launch Goldman Sachs’ retail bank Marcus Support Fintech Business Weekly You can also support Fintech Business Weekly by sponsoring a newsletter or podcast, putting you in front of 93,000+ of the most influential decision makers in banking, fintech, and crypto. Learn more about sponsor opportunities or request a media kit by dropping me an email. Q2 Quarterly Banking Profile: Five Quick Takeaways The FDIC released its quarterly banking profile, which is always worth a read, for the second quarter. The profile provides an aggregate snapshot about the overall health of the 4,238 institutions whose deposits are insured by the FDIC, who, collectively, hold more than $26 trillion in assets and saw a total net income of more than $90 billion in the second quarter. Net income was up 12% vs. Q1 2026, with lower provisions and realized gains on securities helping to drive the improvement, somewhat offset by increases in non-interest expense and applicable income taxes. Overall net interest margin was basically flat quarter over quarter (up 1 basis point vs. Q1 2026), though community banks saw NIM grow by 10 basis points, to 3.81%. Unsurprisingly, given that interest rates haven’t changed, unrealized losses on securities changed little, edging up slightly to $326.7 billion vs. $325.1 billion in Q1 2026. Aggregate credit quality has remained benign, with asset quality actually improving slightly in Q2. Overall, institutions reported a 9 basis point decline in their past-due and non-accrual rate, to 1.44%. Net charge off rate also declined by 2 basis points, to 0.57%. And finally, the FDIC’s deposit insurance fund stands at $161.1 billion, making the DIF reserve ratio 1.48% — above the statutory minimum of 1.35%, but still below the designated target reserve ratio of 2%. [Paid Subscriber Exclusive] Nissan Withdraws ILC App, State Associations Plan BankChain Alliance, FDIC Defines “Unsafe or Unsound Practice” For First Time Automaker Nissan withdrew its application to charter a Utah industrial loan company and its corresponding application to the FDIC for deposit insurance last week, on August 19th. Nissan’s application had been outstanding for more than a year, as it originally applied in June 2025. Recent applications to the OCC to form national banks have been decisioned, one way or the other, substantially more quickly than has historically been the case.
PAD significantly increases risk of AFib, new meta-analysis confirms
Clinicians may want to take a more proactive approach when managing PAD patients to ensure they minimize the risk of new-onset atrial fibrillation.
WATCH: El-Sayed praised ‘beautiful’ sense of community abroad while trashing US as 'White supremacy'
Abdul El-Sayed praised Egypt's community life and called Americans "deeply atomized" in a podcast, adding to resurfaced remarks criticizing U.S. culture.
The Psychology of Tribalism Is Damaging Politics
Since he first walked this earth, man has organized himself into tribes. There is safety in numbers and, along with physical and practical advantages, comes the most appealing benefit: belonging.Politics is no different. With the midterm election looming, examining the psychological forces and incentives that drive tribal behavior can help us understand political movements and electoral outcomes.For most of the human species, the feeling of belonging isn’t just a desire; it is a biological and psychological necessity. We are, after all, social creatures.
Health & Medical Organizations Support Strong Energy Standards
Advocating for practical policies to make it easier to transition to healthier and more efficient appliances for improved indoor air quality in homes.
Intel Crescent Island GPUs Pack Up To 32 Xe3P Cores, Optimized For Agentic AI With Low-Cost LPDDR5X That Reaches Up To 480 GB Capacity
Intel has given the rundown on its next-gen AI inference accelerator, Crescent Island, which packs 32 Xe3 cores and 480 GB of LPDDR5X memory.
Padres Announce Concerning Casey Mize Injury Update During Twins Game
The San Diego Padres lost starting pitcher Casey Mize to injury. The right-hander left his start against the Minnesota Twins in the third inning.The Padres later provided an update on Mize’s status, who left the game with a right ankle sprain. He suffered the injury walking down the dugout steps after the second inning. Update […] The post Padres Announce Concerning Casey Mize Injury Update During Twins Game appeared first on HEAVY.
How a physician with a 1 a.m. bedtime optimizes his health: I try to 'tick all the longevity boxes that I can'
Dr. Ronald Primas, a longevity physician, offers concierge services like developing personalized health plans for clients. Here are his own wellness practices.
Pixel Watch 5 lets you customize double pinch to dismiss alarms, skip music, & more
The double pinch gesture on the Pixel Watch 5 benefits from being able to “Customize actions” across music and alarms.
iPhone Ultra lands September 18 at $2,000 and kills the visible crease
Every foldable phone you have ever held has a crease in the middle of the display, and that crease has been the category's most embarrassing open secret since 2019. Samsung has refined it, minimized it, and shot their devices in lighting specifically designed to hide it. Google's Pixel Fold was a little better. The Honor
Webinar to discuss how Georgia health system improved capacity monitoring efforts
The AHA’s Hospital Capacity Management Consortium will host a webinar Sept. 9 at 1 p.m. ET for capacity management and operations leaders, exploring how Georgia-based Emory Healthcare’s Capacity Command Center improved patient access, optimized throughput and proactively managed systemwide demand.
Publication in Science charts a path to democratized molecular innovation
Blocc chemistry is a new way to make medicines, materials and a range of consumer products that is friendly to robots, AI and anyone. An international team of thought leaders has been assembled to prospectively map out how to keep this technology safe and maximize its potential benefits to society.
The Apophis encounter in 2029: A rare opportunity for planetary science and defense
The near-Earth asteroid Apophis will make an extremely close flyby of Earth on April 13, 2029, at a distance of approximately 38,000 km—an event that occurs on average only once every 7,500 years, offering an unprecedented opportunity for planetary science and planetary defense. However, significant uncertainties remain regarding the physical parameters of Apophis, such as its shape, spin state, internal structure, and material composition, and predictions of tidal effects—including potential orbital changes, spin acceleration, surface material displacement, and dust ejection during the flyby—are highly dependent on model assumptions. Although multiple nations have planned exploration missions, how to coordinate global observational resources within the limited time window, optimize rapid-response mission architectures, and translate scientific understanding into effective planetary defense strategies remain critical challenges to be addressed.
Could GLP-1s help treat opioid use disorder? Vanderbilt Health study now enrolling
The study, Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB), is a double-blind, randomized, placebo-controlled trial conducted through the National Institute on Drug Abuse’s Clinical Trials Network.
Cramorant Form Change Mechanic in Pokémon GO Explained
Cramorant Form Change Mechanic, counterattacks, and timing tips to maximize Gulping and Gorging Form value in Pokémon GO battles.
Imaging experts 3D-print specialized MRI sensors at fraction of standard cost
“By making customized MRI equipment faster and more affordable to produce, we have the potential to bring better imaging to patients who have traditionally had fewer options," says USC's Yasser Khan, PhD.
What Happens to Your Bone Health When You Take Vitamin D With Calcium?
Vitamin D helps the body absorb calcium, so taking them together can optimize their benefits.
Microsoft confirms that it will begin shipping major Windows 11 Taskbar and Start menu updates in the next few weeks: Big OS update enters final preview phase before public rollout begins
The ability to move and resize the Taskbar, as well as customize the size and layout of the Start menu should begin rolling out imminently, if the latest Windows 11 preview builds are anything to go by.
If you run a solo business, here’s how AI agents can help you
Four ways to maximize the technology for your specific needs.
Czinger debuts topology-optimized brakes with 21C Spyder
Czinger used topological design and additive manufacturing to make the brakes.
AI needs science’s search history
“Actually, that’s where the gold is,” said Alasdair Russell, my graduate school friend who leads a pre-clinical genome editing group at Cambridge. He was talking about the winding road of science that is omitted from published papers. “When you’re discussing how to do the experiment, and why this way is better than another way, and what does the data really mean? I know what it shows, but what does it mean?” At RAAIS 2026, he described how his group has begun logging the twisting path of discovery as it happens, recording the verbal and written exchanges that normally disappear. Ideas become nodes in a living graph: they branch when a meeting produces two plausible experiments, merge when separate lines of evidence converge, and go dark when someone quietly stops pursuing them. In his implementation, one agent scores novelty, while another tries to learn “how scientists think and how they navigate through a complex world of data,” so that high-potential nodes can trigger deeper investigation. As frontier AI labs deploy agents toward scientific discovery, giving AI authentic scientific taste remains a trillion-dollar dilemma. The bottleneck is that the record we have kept for centuries of science might be insufficient to get us there. The experiments that never make the paper Peter Medawar, 1960 Nobel laureate and “father of transplantation,” asked in 1963 whether the scientific paper was a fraud, and answered yes: the form of the paper misrepresents the thinking that produced it. Sixty years on, the diagnosis is unchanged. A paper presents a clean progression from hypothesis to result to conclusion. Lost along the way are the unconventional theories, the abandoned or unaffordable methods, and the underwhelming and inconclusive data. It reads like a browser history with every dead end deleted: the ten open tabs, the four rephrased queries, the wrong turn down a subforum. All scrubbed, leaving one clean path from question to answer as the canonical path. What has changed since then is that the discarded material is now worth something. No high-impact journal wants these artifacts, but raw trial and error is the most likely source of the training data required to develop scientific intuition, or what researchers call taste. Earlier attempts to capture the discards were motivated by scientific integrity. The Journal of Negative Results in Biomedicine launched in 2002 to publish rigorous studies that disputed established models or exposed ineffective treatments. Its archive preserved negative conclusions after they had become papers, rather than the live alternatives and arguments that produced them. BioMed Central closed it in 2017, saying the mission had been served now that other journals publish null results. A less generous reading is that in fifteen years it published around 200 papers because almost nobody wants to read a negative result, let alone write one up when it will not count toward academic tenure. AI models are different. Even an uninteresting negative result can be useful, provided it is labeled. Earlier this year, Anthropic put a version of this to the test. The company pulled 129 decision points from real Claude Code sessions between January and March 2026, showed models the work up to a human detour, and asked what should happen next. Claude Mythos Preview beat the human choice 64% of the time, while Opus 4.5 managed 51%. The comparison was tilted toward the models because Anthropic deliberately chose moments where the human decision had room for improvement. On 127 further scenarios where the human action was already strong, the models improved on it only about 20% of the time. The study was possible because Anthropic’s researchers work inside a tool that logs by default. The reasoning, detours and outcome are produced in the same working environment. Biology has no equivalent. Its reasoning happens in hallways, at benches, in Slack threads and on whiteboards, while the outcome arrives weeks later somewhere else. The record has to emerge from the work itself. Ask scientists to reconstruct it afterwards and we’ll create another polished account. Subscribe A log is not a label Before any of this becomes training data, a negative result has to say what failed. The first paper published in the Journal of Negative Results in Biomedicine examined 234 negative studies across five leading medical journals. Only 30% discussed statistical power, and half clearly defined a primary outcome. Tell a model an experiment failed, without telling it whether the assay was underpowered, a reagent had degraded, or the hypothesis was simply wrong, and it will learn noise with confidence. Decision histories have a second missing label too. When a lab considers five experiments and runs one, only the chosen branch returns an outcome. The other four are experimental counterfactuals. Researchers call this the selective labels problem: the data reveal results only for the actions someone chose to take. Such a record can teach a model to imitate a lab’s taste, but it cannot establish that the taste was good. It also smuggles local constraints into general lessons. A lab that never ran cryo-EM because it did not own a microscope teaches a model that cryo-EM is rarely the right call. Alasdair’s nodes preserve the candidate set, which is the necessary first step. To be useful, each decision record needs six fields: The evidence available at that moment, and nothing that arrived later. The candidates considered, including the ones dismissed in a sentence. For each candidate: the expected result, the confidence attached to it, and the cost in time and money. The route chosen, and the reason. What happened next. How the evidence changed the scientist’s view. These must be timestamped before the outcome, because hindsight turns uncertainty into inevitability. Disagreement also has to survive. Averaging three scientists into one clean rationale reproduces exactly the information loss we are trying to fix. But there is an obvious failure mode here. Once decisions are logged and scored, people log for the record post-facto. Anyone who has watched an electronic lab notebook fill up with retrospective tidying knows how quickly a research tool becomes a compliance exercise. A record that costs a scientist ten minutes of honest reflection per decision is worth far more than one that costs an hour of performance. A publication initiative called Registered Reports offers a useful starting point. Here, researchers submit their rationale, methods and analysis plan for peer review before the data exist, and the journal commits in principle to publish if they follow the approved plan. Nature has now expanded the format across every field it covers. This approach to paper writing timestamps intent before the outcome, but it freezes one plan. A useful search history must also preserve how the plan changed, which alternatives were rejected, when, and on what evidence. Subscribe Run the runner-up Autonomous labs show what happens when decisions and outcomes are connected in a loop. Liverpool’s mobile robotic chemist ran 688 experiments over eight days in a ten-variable formulation space. A batched Bayesian search used each result to choose the next experiments and found photocatalyst mixtures six times more active than the starting formulations. Every completed experiment changed what the system did next. The robot optimized within a goal and search space that humans had already chosen. It did not decide which scientific question mattered. So what this work demonstrates is narrower, but still useful: a search history pays off when the options return standardized outcomes quickly. Open-ended biology is harder because branches can take weeks and the discarded alternatives may never be run. Some exploration therefore has to be bought. Where two branches are plausible and the stakes justify the cost, a lab should sometimes run the runner-up. Otherwise the record captures what today’s scientists usually chose and stays silent on what they systematically overlooked. A funder could ring-fence a small fraction of a grant for the branch not taken, provided that the decision record and the outcome are both deposited. That costs money, but so does having every lab rediscover the same abandoned path. Test whether taste transfers When it comes time to evaluate if our new AI system exhibits taste, the comparison should run across laboratories and fields. At selected decision points in a live research campaign, we should freeze the six fields: the evidence, the candidates, expected results, confidence, costs and the choice made. Experts then rank the options before the outcomes are known, and those outcomes are checked independently later. We could give models one of two diets - papers alone, or papers plus decision histories - and ask them to rank the next experiment on unfamiliar projects. Then, we score information gained per dollar and week, calibration, and how quickly weak branches are abandoned. If histories improve choices only inside the lab that produced them, they amount to useful organizational memory. If they improve choices on unfamiliar problems elsewhere, Alasdair’s group will have captured something science has never managed to write down: a transferable record of taste. Until that happens, a scientific search history is a promising record, not yet a training set.
Dodgers Considering New Pitching Role for Ohtani’s Return
Los Angeles Dodgers manager Dave Roberts hints at utilizing Shohei Ohtani’s elite arm in high-leverage, multi-inning bursts to maximize impact.
Razer Unveils the Naga V3 Pro MMO Gaming Mouse
Razer, the leading global lifestyle brand for gamers, today announced the Razer Naga V3 Pro, the latest evolution of its iconic MMO gaming mouse. Built to adapt across game genres and playstyles, it features three swappable magnetic side plates, more ways to customize controls, upgraded...
Vanderbilt Health evaluating vaccine for C. difficile for people 65 and older
Participants in the study will be randomized to receive two C. difficile vaccine doses six months apart, or a placebo, to learn if an investigational vaccine is safe and can help prevent C. difficile infection in persons age 65 and older.
Seedy K’s Preseason Prattle: Oligarchs, Senators & Cards’ Greatest Villain
The oligarchs who run college football met this week to begin to perhaps decide the future of the sport. How to maximize revenue. Especially for the oligarchiest among them, Big Ten, SEC and that school Paul Hornung attended. They met virtually. Though the meeting was originally set for the new Four Seasons Resort at Del […]
Reimagined night-call model boosts interventional radiologist well-being
Stanford University Medical Center has sought to alleviate burnout by rearranging its call model to minimize strain on physicians.
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
Honoring Indigenous Midwives: Recognizing Indigenous Women’s Role in Delivering Family and Community Healthcare Across the World
Indigenous midwives provide trusted maternal and community healthcare, preserving ancestral knowledge while supporting families. Growing recognition, training, and integration into health systems are improving outcomes for women and children worldwide.
Did Caviar just spill the beans on the iPhone Ultra and the iPhone 18 Pro design, specs and release date?
The luxury phone customizer has fresh new “insider” details pages alongside its now-live pre-orders for the phones. It’s not uncommon for Caviar to kick...
Using AI has an environmental impact — here are 4 ways you can minimize it
Escalating use of tools like Gemini and ChatGPT saps more and more power. Experts offer some tips on how to consume less.
Why Businesses Should Account for Cyberattacks When Implementing AI
AI can limit a company’s productivity by making it more vulnerable to cyberattacks, necessitating the use of AI security and other practices that minimize the attack surface.
Android Canary 2608 lets you customize Quick Settings layout on Pixel
Google today is rolling out Android Canary 2608 with the ability to customize the Quick Settings layout by...
Dolby Vision 2 Is Officially Available On Select Hisense TVs
Dolby Vision 2 includes a new algorithm that optimizes content on a scene-by-scene basis.
Padres' Casey Mize: Slated for debut Wednesday
Padres' Casey Mize: Slated for debut Wednesday
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
iOS 27 adds four new ways to customize your iPhone’s Lock Screen
iOS 27 adds four new Lock Screen customization options, including AI wallpapers and a movable clock. Here's how they work.
Microsoft Is Quietly Deleting 32 GB RAM Recommendation for Windows 11
Microsoft is retroactively removing documentation from its website and materials that mention 32 GB of RAM as a recommendation for new PC builds or purchases. Instead, the company is now emphasizing 8 GB devices that are optimized to run Windows 11 smoothly, even with that RAM configuration....
Living in Italy cured my 10,000-step obsession
After moving to Florence, I realized walking didn't have to be something I constantly tracked or optimized to be healthy.
Kenley Jansen Sends Defiant Message After Tigers Trade Deadline
Kenley Jansen challenged the Tigers to play with a chip on their shoulders after the trades of Tarik Skubal and Casey Mize.
Katerina Guerraz
Katerina Guerraz is Executive Vice President, Chief Strategy Officer and Head of Enterprise Affairs of CVS Health
Google tests new features designed to make the Google Messages app easier to use
For the first time ever, the Google Messages attachment sheet icons can be customized and made to take up a full page.
Ukraine uses business principles to maximize Russia’s casualties and economic costs, potentially crushing its will to keep fighting, RAND says
Ukraine has KPIs for the military—just like corporations, which use them to track output from employees or subsidiaries.
Renewables in Europe: TotalEnergies Acquires Shell’s Renewables Business and Sells a 50% Stake in a Portfolio of Developed Assets to KKR
Paris, August 3, 2026 – In line with its Integrated Power strategy in Europe focused on selected deregulated markets, as illustrated by the recent transaction with EPH, and with its business model designed to optimize capital allocation in renewables, TotalEnergies announces the signing of two transactions in Europe: The…
Federal Policy Priorities To Strengthen Rural Health and Maximize Rural Health Transformation Program Investments
Executive Summary Rural health care in the United States is at an inflection point. The Rural Health Transformation Program (RHTP), enacted as part of H.R. 1, is a $50 billion, five-year investment designed to help states improve access, quality, and outcomes by transforming rural health care delivery. This investment takes place alongside an estimated $137 … Continued
Microsoft to optimize Windows 11 for PCs with 8GB of RAM
Microsoft is preparing Windows 11 optimizations designed to improve performance on PCs with 8GB of RAM, targeting high idle memory use. The updates will roll out gradually, with broader improvements expected by the end of 2026.
Chrome for Android now lets you set a custom New Tab Page background
Like on desktop, Chrome for Android now lets you customize the New Tab Page with a background image or theme.
The new "science golden age" looks suspiciously like a grift
This edition of PN is made possible by paid subscribers. Become one ⬇️ 🚀 Subscribe to PN 🚀 The Trump regime is trying to usher in a “Golden Age in Science” where scientific research is run like a Trump family business, artificial intelligence is all that matters, profit is everything, and expertise is for chumps. Or at least that’s the vision emerging from a new 123-page “Report to the President” from Michael Kratsios, the Director of the White House Office of Science and Technology Policy. In a normal administration, you could probably skip over learning about a science policy document — but this is no normal administration, and this is no normal science policy document. Instead, it’s Trump’s attempt to end the actual golden age of science that was kicked off in 1945 with the publication of '“The Endless Frontier” by Vannevar Bush. [ ](https://www.publicnotice.co/p/harmeet-dhillon-portland) [ Harmeet Dhillon demonstrates danger of posting through it ](https://www.publicnotice.co/p/harmeet-dhillon-portland) Liz Dye · Jul 29 [ Read full story ](https://www.publicnotice.co/p/harmeet-dhillon-portland) Bush, at President Franklin Delano Roosevelt’s request, laid out a vision of federal support for science that centered on funding universities to do basic research, saying that as long as those institutions were “vigorous and healthy and their scientists are free to pursue the truth wherever it may lead, there will be a flow of new scientific knowledge to those who can apply it to practical problems in Government, in industry, or elsewhere.” Kratsios’s report is supposed to be the successor to Bush’s, and even apes the format, but this isn’t really a document about science policy. It’s one about ending science research as we know it in favor of shoveling cash at big tech companies. While it might be temping to wave this away as an aspirational policy document, Trump has already begun to shift billions in research funds to AI projects and has taken a hatchet to science funding across the board. He’s teed up the shift Kratsios proposes here, and since neither Congress nor the Supreme Court seem inclined to stop him from doing whatever he wants with taxpayer money, it isn’t doomering or hyperbole to say we are staring down the barrel of a world where the only “science” the government intends to support is for-profit tech and defense advancements. Science for dummies Part of how you can tell this isn’t a document about science is that you are immediately faced with an absolute wall of business-speak of the worst sort. Did you know we must “tightly couple our science and technology enterprises to ensure that groundbreaking ideas invented in the United States are rapidly prototyped, tested, manufactured, and scaled domestically”? You do now! That tone isn’t surprising, because Kratsios has no background in science or research. He has a bachelor’s in political science and spent most of his career working for Peter Thiel at Thiel Capital. After a stint in the first Trump administration as Chief Technology Officer, where he also did not do any science, Kratsios was tasked in 2020 with overseeing the Pentagon’s research budget for a brief time, a position that, as the Wall Street Journal put it, “carries a great deal of power in terms of dictating investment allocations.” He spent the Biden years at Scale AI as “head of strategy,” which you will also note is neither a science nor a research job. But Scale AI has contracts with the Department of Defense and, as the Washington Post wrote in 2023, “has been aggressively pitching itself as the company that will help the US military in its existential battle with China.” And now you have the necessary background for our new golden age, which is going to be a golden age of taking money away from scientists and universities and giving it to companies like Scale AI. A note from Aaron: Working with brilliant contributors like Lisa takes resources. If you aren’t already a paid subscriber, please become one to support our work. 👇 Subscribe In a genuinely galling move, Katsios spends a lot of time slamming universities because of “administrative burdens on researchers” and the “well-documented inefficiencies” in academia, the message being that those damn universities waste the time of amazing researchers with paperwork. Except it’s the administration that is attempting to impose inefficient, unnecessary burdens on those researchers with a proposed Office of Management and Budget rule that would require senior political appointees to approve every science grant and ensure it aligns with Trump’s personal priorities. Researchers would also have to seek prior government approval to attend conferences or publicize their research. And political appointees could terminate any grant at any time if they feel like it. [ ](https://www.publicnotice.co/p/omb-rule-science-funding) [ The murder of expertise ](https://www.publicnotice.co/p/omb-rule-science-funding) Lisa Needham · Jun 11 [ Read full story ](https://www.publicnotice.co/p/omb-rule-science-funding) But when it comes to AI, we’re going to “restore permissionless innovation.” The report proposes to give lucky ducky innovators a pile of cash up front for grants lasting five years or longer, saying “awards should be fully-funded in year one, with all resources earmarked upfront, to minimize administrative burdens and reduce pressure for researchers to generate intermediate results to secure continued funding.” Yeah, wouldn’t want to have to make the Very Special Tech Bros show results or get money parceled out year by year like the plebes at universities. The report also proposes that we should have “fast grants” with “simplified applications requiring just a few pages of writing” because that is definitely how science works, just writing a bit off the dome and getting some cash. [ ](https://www.publicnotice.co/p/trump-ai-action-plan-altman-llms) [ Tech elites are turning AI into ChatGPTrump ](https://www.publicnotice.co/p/trump-ai-action-plan-altman-llms) Paul Waldman · July 29, 2025 [ Read full story ](https://www.publicnotice.co/p/trump-ai-action-plan-altman-llms) Oh, and we should have prizes and challenges, where multiple teams compete. The proposed prizes include incentives like “advance procurement commitments,” which means the federal government agrees to buy whatever is being developed. There’s also “regulatory fast-tracking,” making sure all those great AI thingies don’t have to wait too long to be unleashed on a market. These aren’t incentives to do science. These are incentives to develop things with tax dollars that you can then sell to the government for more tax dollars. In the suggestion that might be the most unhinged, the most very opposite of how both government and research work, our new age will include “golden tickets.” That’s where an individual reviewer in an agency — yes, just one person — can “recommend unconventional proposals that may not pass consensus-driven review panels” because somehow this will “surface valuable ideas too divisive for committees and attract higher quality reviewers by empowering them to exercise independent scientific judgment.” Yes, that’s saying that a random person in an agency should be able to shovel money at some idea even if it can’t pass a review panel, and that the opportunity to do so will attract better employees because apparently all the best minds in science are chomping at the bit to be allowed to unilaterally fund AI research based on their personal vibes. But that isn’t at all how actual science works, and actual scientists aren’t unhappy about review panels. They work collaboratively, not siloed in some secret race to create the next AI chatbot. A 2020 study by the National Bureau of Economic Research examined whether peer review panels succeed in helping agencies predict which research ideas will best advance science. Peer review was better at finding “diamond in the rough” applicants than a single government program official. How about that. Trump always wants a taste It’s painfully clear that what Katsios is trying to do here is turn the whole of government science research and funding into the sort of “move fast and break things” paradigm that is the hallmark of big tech. That method works to line the pockets of tech executives, but it isn’t science. There’s a reason the government funds different kinds of research than private tech companies do. What Katsios either fails to understand or deliberately ignores is that the federal government is the main funder of basic research precisely because it can take a long time for it to bear fruit and is not intended to be profitable as such. “Basic” here does not mean rudimentary or simple, but rather research that is designed to advance scientific knowledge instead of achieving a specific outcome or product. Big tech companies don’t widely fund that sort of research, because it doesn’t make them money. Industry dollars account for only about 20 percent of basic research funding, while the government contributes around 60 percent. Big tech companies and startups do, however, rely on and benefit from that basic research. A 2019 study found that 35 percent of all patents obtained by venture-backed startups from 1976 to 2016 cited federally supported research. Basic research funded by the NIH contributed to every single drug the FDA approved from 2010 to 2016. [ ](https://www.publicnotice.co/p/trump-saudi-nuclear-deal) [ The Saudi nuclear farce and governance by whim and meme ](https://www.publicnotice.co/p/trump-saudi-nuclear-deal) Noah Berlatsky · Jul 27 [ Read full story ](https://www.publicnotice.co/p/trump-saudi-nuclear-deal) Unlike inventing the next ChatGPT, actual science is slow and iterative. Government funding of research that, on its face, would not appear to lead to any big new invention is actually what underpins those big new inventions. If the government hadn’t funded research into desert lizard venom, we wouldn’t know about semaglutide, and we wouldn’t have Ozempic. If research scientists hadn’t studied how bees optimize nectar foraging within a colony, we wouldn’t have the algorithm that assigns internet traffic across computer servers. The report assiduously ignores that a symbiotic, profitable relationship between the federal government, universities, and private companies already exists. Each federal research dollar generates about $1.50 to $3.00 in long-term economic benefits. The $36 billion the government awarded in NIH research funding in fiscal year 2025 generated $94 billion in new economic activity. Trump’s proposed new golden age is intended to strip those billions from universities, resulting in the dismantling of departments and the shuttering of labs. But Katsios has a plan for that: Universities should just become trade schools to churn out no-show STEM degrees! “Require universities and community colleges to embed practical technical training and externships into STEM curricula. Let hands-on experience and industry credentials count toward degrees.” It’s quite the feat to, on the one hand, strip schools of funding for scientific research while simultaneously demanding to control what is taught and, oh, also, colleges need to give degrees to employees at big tech companies just for being employees at big tech companies. The new golden age would also exacerbate the brain drain Trump’s policies have already caused. Nature found that in the first quarter of 2025, US scientists submitted 32 percent more job applications abroad than in 2024. A March 2025 poll by Nature of roughly 1,600 scientists found that over 1,200 said they were considering leaving the country. Europe is investing $565 million to make it a “magnet for researchers” and provide funding for scientists who relocate. The new golden age is also about embedding Trump’s xenophobia into the fabric of American science. The report complains of an “over-reliance on foreign students” that “creates a security challenge our institutions are ill-equipped to address” and that a “reliance on foreign talent sidelines American students.” This is, to put it mildly, nonsense. International students pay far higher tuition and often receive no financial aid. Their tuition dollars are what make it possible for American students to get financial aid. In the 2023-2024 school year alone, international students contributed $43.8 billion to the US economy and supported over 378,000 jobs. Those 1.1 million international students accounted for only six percent of the total number of students in higher education that year, but were such an economic engine that for every three international students, one job was created or supported. It’s impossible not to wonder whether part of Trump’s loathing for universities and their leading role in scientific research is that there is no way for him to corrupt the process and make money off it in the same way he can by giving millions and billions to Silicon Valley types who, in turn, give him millions in cash. There’s no way for his children to invest in universities that the government then gives no-bid contracts to, fattening the family’s bottom line, which is pretty much the Trump sons’ current venture capital practice. Trump and Katsios’s view of science is narrow, cramped, and wrong. We’re not in a crisis, we’re not a failed state. We’ve been a science superpower for decades, and the only thing that threatens that is Donald Trump. Tech bros are already living high off the hog in this administration. They don’t need any more of our tax dollars. Hopefully this new golden age never comes to pass. Thanks for reading Public Notice. This post is public so feel free to share it. Share We’ll be back with more tomorrow. If you appreciate today’s PN, please do your part to keep us free by signing up for a paid subscription. 🚀 Subscribe to PN 🚀 Thanks for reading, and for your support.
Praxis Profit launches new executive advisory service to help Tahoe business owners strategically maximize profitability
SOUTH LAKE TAHOE, Calif. – Praxis Profit, a boutique strategic chief financial officer advisory firm, announced today its full-suite of financial decision-making consultancy service including cash flow visibility, margin protection and executive level financial decision-making...
All the Ways You Can Make Reading on Your Phone Easier
Tired of eye strain? These tips will help optimize your smartphone for marathon reading sessions.
Falcons Reacts Survey: What is Tua Tagovailoa’s outlook?
How will the former top-five pick maximize his fresh start in Atlanta?
Florida-Based Science and Technology Company Crescel Announces Landmark Peer-Reviewed Medical Publication
Crescel LLC, a Florida-based innovative science and technology company, today announced publication of its landmark PubMed-indexed, peer-reviewed clinical study showing that its biobotanical technology produced statistically significant improvements over the leading prescription standard of care for rosacea in a randomized, double-blind, controlled clinical trial. Published in the Journal of Cosmetic Dermatology, the study represents a major scientific milestone for the company's pioneering prop
Booking.com for Business Offers Business Travel Jet Lag Calculator
Tool aims to minimize syndrome
Samsung's Galaxy Z Fold 8 Is for Those of Us Who Can't Stop Scrolling
With a new 4:3 aspect ratio optimized for both horizontal and vertical content, Samsung's wide book-style foldable could be better suited to the way we actually browse, watch and consume content.
Smart Tips to Maximize Your NASCAR Weekend at New Hampshire Motor Speedway
At New Hampshire Motor Speedway, fans get more than just racing — they get great value. New England's only NASCAR Cup Series weekend features affordable tickets, free parking, flexible camping options and inclusive entertainment like live music and fan experiences.
iOS 26.6 Prepares Your iPhone for iOS 27
iOS 27 includes a rebuilt search architecture for Siri AI. As a result, iPhones running the iOS 27 beta go through a re-indexing process that can take many days to be completed, but iOS 26.6 should help to speed things up for users who skip the beta. iOS 26.6 "optimizes the Spotlight index to prepare for iOS 27," according to Apple's release notes for the update, which will likely be released next week.
Shaky political "science": breakdown of the peer review process
[This article is the latest in our “Shaky Political Science” series. In our 38 page report, “Shaky political ‘science’ misses mark on ranked choice voting,” released in December 2025, we examined over 40 studies focused on ranked choice voting (RCV). Many of these studies suffered from puzzling research methodologies, poorly constructed surveys, unrealistic simulated elections, cherry picked data and faulty analyses that often were contradicted by results from real-world elections (a link to our full paper is here). Here are links to the first four articles in our series: the first one summarizing the overall results of our report; the second one analyzed a study co-authored by University of Minnesota academic Larry Jacobs, which was one of the most error-prone of all the research we reviewed in our report; a third article showing an admirable example of two political scientists holding two other political scientists accountable for their flawed, sloppy research; and a fourth article that analyzed seven studies sponsored by New America’s political reform program that deployed flawed methodology based on “simulated” elections instead of real-world elections, which when combined with some basic misunderstandings of RCV, produced odd and misleading results]. In this fifth article in our “Shaky Political Science” series, we examine two flawed studies on the impact of RCV on voter turnout authored by San Francisco State University professor Jason McDaniel. McDaniel’s research in these two papers stands out for its puzzling methodology, inadequate and cherry-picked data, and faulty analyses that not only misunderstands ranked choice voting but reflects a basic misunderstanding of politics in general. The first of the McDaniel studies actually passed through a peer review process and then was subsequently published by the Journal of Urban Affairs, despite its obvious errors. It is perplexing that a jury of peer political scientists did not catch the errors and send it back to McDaniel for a rewrite or outright rejection. This calls into question the credibility of the peer review process itself. The peer review process is supposed to represent the intellectual pinnacle of the profession – a way for academics to certify the quality of each other’s work, and to act as a check against sloppy research. In the case of the McDaniel study, the peer review process failed. Yet his flawed study has been cited dozens of times by other political scientists in their own flawed works — an unvirtuous circle of academic research. Here is the first Jason McDaniel study that we analyzed: “Writing the Rules to Rank the Candidates: Examining the Impact of Instant-Runoff Voting on Racial Group Turnout in San Francisco Mayoral Elections,” by Jason McDaniel, 2016, Journal of Urban Affairs. This study covered San Francisco’s use of ranked choice voting (RCV) in mayoral elections, purporting to show that RCV reduces voter turnout overall, increases voter errors, and has a negative impact on “marginal populations,” i.e. racial minorities, mainly as the result of the alleged complexity of RCV asking voters to rank candidates and having to be familiar with multiple candidates and related dynamics. McDaniel reached these conclusions by examining five San Francisco mayoral elections taking place in odd years (i.e. where there are no federal or state races on the ballot) from 1995 to 2011, comparing three earlier non-RCV races (in 1995, 1999 and 2003) with the later two RCV races (in 2007 and 2011). Only two RCV races were studied, and as McDaniel acknowledged, only the contest in 2011 was “competitive” (that contest in 2007 was the first mayoral election using RCV, and incumbent mayor Gavin Newsom won easily in the first round of counting, earning 74% of first choices and far ahead of the second place candidate who had just 6.3% of first choices). Yet even the allegedly competitive contest in 2011was won by an incumbent with a landslide margin of nearly 20 points. No other elections were studied by McDaniel, even though San Francisco elects 17 other offices besides mayor with RCV, including the 11 seats on the Board of Supervisors (the name for the city council) in even years, and six other citywide offices in odd years. Previous academic research has found that competitive elections can stimulate greater voter involvement and higher turnout. For unexplained reasons, this study ignored at least 34 other RCV races between the years 2004 to 2011, many of which were very competitive and had high voter turnout. Instead, McDaniel’s analysis based its conclusions on data from only a single, marginally-competitive mayor’s race using RCV. These 2007 and 2011 mayoral elections were the only two RCV elections that McDaniel used as the sole basis for his small data set to determine the impact of RCV on voter turnout. Despite having no meaningful data to inform his study, McDaniel nonetheless concluded that RCV lowered turnout when compared to the previous three mayoral non-RCV elections using two-round runoffs. Then, using the same inadequate database of San Francisco elections, McDaniel also found that “Instant-runoff voting is associated with a significant decline in Black voter turnout and White voter turnout…On average, Black voter turnout decreases by 18 points and White voter turnout decreases by 16 points …” But how could he credibly arrive at that conclusion when his study was based on voter turnout in two RCV contests that were not even remotely competitive? Beyond that, McDaniel tacitly admits that the key determining factor driving Black voter turnout was not RCV vs non-RCV elections, but the presence of a viable Black candidate. McDaniel wrote, “Black voter turnout was about 17 percentage points higher for the two elections that featured an African American candidate compared to the three elections that did not” — but one of those three elections did not use RCV. The same dynamic was present for White voter turnout, in which higher turnout was not correlated with RCV vs non-RCV elections, but the presence of a viable White candidate. Beyond that, McDaniel’s voter turnout results, whether correlated with the race of the candidates or RCV vs non-RCV elections, showed no clear patterns. In his Figure 1, he shows low Asian voter turnout in the non-RCV elections in 1999 and 2003 when there was no viable Asian candidate running, but in the 2007 mayoral election using RCV, there is still no viable Asian candidate, yet Asian turnout increases dramatically. For Latinos, voter turnout is virtually the same in 1999 (no viable Latino candidate, non-RCV elections), 2003 (leading Latino candidate, non-RCV elections), 2007 (no viable Latino candidate, RCV elections) and 2011 (leading Latino candidate, RCV elections). Meanwhile White voter turnout increased dramatically from a low in the 2007 mayoral election, in which the leading candidate was a white incumbent, to the 2011 election in which there were no leading white candidates that finished any higher than sixth place with 5.6% of the vote. Clearly other factors were determining voter turnout than either the race of the candidates or RCV vs non-RCV elections. Despite these inconsistent findings, McDaniel boldly marches forth to render conclusions about the impact of RCV on different groups of racial voters, even though his conclusions are not remotely supported by his data. This looks like the worst kind of “data cherry picking” to cover up a puzzling conclusion based on a poor data set involving only two RCV elections, neither of which were remotely competitive. McDaniel’s cherry picking didn’t stop there. In calculating voter turnout for the three non-RCV mayoral elections in 1995, 1999 and 2003, he failed to mention that in each of these years there was a two-round runoff election, with a first round election in November in which no candidate garnered a winning majority of the vote, followed by the decisive runoff in December. So there were two non-RCV elections in each election year. But McDaniel only decided to include one of the two elections in his data set, apparently the December runoff in each year (which had higher turnout in two out of the three mayor’s races, and lower turnout in the third). So he ignored the November 1995 election, the November 1999 election when turnout was only 45 percent, and the November 2003 election when turnout was only 45.7 percent. This is flawed methodology based on blatant cherry picking, since McDaniel simply omitted three elections worth of data that did not fit within his frame. His study should never have made it through a peer review process, and it is an embarrassment to political science that not only was it approved for publication, but it has been uncritically cited by dozens of other political scientists. Share A “study” without wider context or credible data Lacking a data set that included even a single competitive RCV mayoral race, McDaniel declared that RCV lowered voter turnout in 2011, when turnout was 42.5 percent. But he also ignored -- or did not realize -- that voter turnout in mayoral elections during 2011 had sharply declined in all big cities, including far more steeply in nearby Los Angeles and other cities. In fact, San Francisco’s election in 2011 had the second highest turnout of any mayoral election in the nation’s 22 largest cities from 2008-2011. Was 2011 just a particularly low turnout year all across the country, perhaps because the country was still reeling from the aftermath of the housing market collapse in 2008-2010? McDaniel ignored this factor and did not search for alternative explanations beyond his flawed thesis. Furthermore, while McDaniel suggested that RCV leads to more “overvotes” – which is an invalidated ballot in which a voter, in either a non-RCV or RCV race, makes a mistake and selects two candidates for a single choice – he failed to address that in the June 2012 US Senate primary contest, which used the typical “one-choice” plurality method and did not use RCV, there was more than five times as many overvotes in San Francisco and Oakland than in the RCV mayoral elections in those cities. Additionally, turnout had been significantly higher and more representative in RCV elections for the San Francisco Board of Supervisors races -- that McDaniel didn’t even bother to study -- as compared to previous “delayed two-round runoffs” for those offices, often higher by as much as 40% in the RCV races. Perhaps the most surprising irony was that an earlier study co-authored by McDaniel (Overvoting and the Equality of Voice under Instant-Runoff Voting in San Francisco by Francis Neely and Jason McDaniel, 2015, California Journal of Politics and Policy) found that overvotes are often more common in lower-income precincts, but that the pattern of overvoting is similar in both RCV and non-RCV contests. Wrote Neely and McDaniel: “[Overvote] errors appear to be a function of complexity in general and not IRV per se…. the pattern of overvoting is similar in both IRV and non-IRV contests…Even among votes cast in a top-of-the-ticket race like U.S. Senate, overvoting occurs in an uneven fashion” (IRV, or ‘instant runoff voting,’ is another name for ranked choice voting in single-winner contests). So McDaniel not only contradicted his own conclusion in his earlier study with Neely, but the earlier study had been an important corrective for one of the most frequently made mistakes made by anti-RCV political scientists – a continual failure to provide crucial context by pairing a comparative analysis of real world RCV elections with an analysis of real world plurality or other electoral methods. Unfortunately McDaniel’s earlier study does not get cited much by other researchers, and McDaniel did not even cite it in his own flawed study analyzed above. Incredibly, McDaniel cherrypicked McDaniel, even as his flawed study has been cited dozens of times. Despite being a textbook example of poor political “science,” featuring both inadequate as well as cherrypicked data, the shelf life of McDaniel’s study has been extended endlessly by other political scientists and media outlets who have cited it uncritically. Equally troubling, the Journal of Urban Affairs put this paper through its peer review process and published it despite its numerous flaws. McDaniel gets it wrong, Part II Not content with producing one shoddy, confused paper, McDaniel produced another one a few years later, here is the link: Electoral Rules and Voter Turnout in Mayoral Elections: An Analysis of Ranked-Choice Voting by Jason McDaniel. San Francisco State Univ. (McDaniel, 2019). In this paper, McDaniel extended his previous flawed research focused on San Francisco, about voter turnout and voter impact, to multiple RCV cities through the 2018 elections. In his data set he included San Francisco, Minneapolis, St Paul, Oakland, Berkeley, San Leandro and Santa Fe. He then compared their turnout in mayoral elections to non-RCV cities, and to mayoral elections in those cities held before first RCV usage, and concluded “a significant decrease in voter turnout of approximately 3–5 percentage points in RCV cities after the implementation of RCV.” But he replicated many of the same mistakes as his first study presented above. While in this study McDaniel attempted to distinguish between various factors, such as odd year vs. even year elections, competitive races vs. noncompetitive, contests with open seats and other factors, the analysis is superficial and inadequate. He attempts to incorporate so many often-conflicting variables that his conclusions are once again unsupported by the actual data, and ultimately unconvincing (this second study never underwent a peer review process). For example, McDaniel declared that for RCV cities “in elections that are more competitive than average (margin of victory less than 20%), there is no significant RCV effect on voter turnout.” Yet McDaniel is a professor in a city, San Francisco, in which the 2018 special election using RCV to fill a mayoral vacancy was exceedingly close, decided by a margin of only one percentage point, and resulted in the second highest turnout in San Francisco history for a mayoral election. Illustrating the complexity involved in assessing the critical factors in turnout, that special election was held on the same election day as federal and state offices, which tends to boost turnout. Yet more voters participated in that RCV mayoral election than voted on the same day in the non-RCV primary for governor in which former San Francisco mayor Gavin Newsom was running. Even more puzzling, in this study McDaniel inaccurately cited his own previous study from 2015 with Neely. McDaniel wrote, “Neely and McDaniel (2015) examine individual ballot image files within a natural experiment, and find higher rates of ballot errors in RCV elections compared to non-RCV elections” (emphasis added). However, we quoted from that 2015 study several paragraphs above, and in actual fact Neely and McDaniel actually concluded the opposite -- that the pattern of overvoting – which is the most common form of ballot error – is similar in both RCV and non-RCV contests. McDaniel also ignored the fact that in Bay Area RCV elections held in even years – at the same time as federal and state elections, when turnout is highest -- the “undervote” (that is, the dropoff in ballots cast for governor or mayor) has declined, which contradicts his thesis that the act of ranking ballots in RCV elections is too complex and presents a barrier for certain demographics of voters. To his credit, McDaniel actually acknowledged another contradiction in his own paper, which found a negative RCV turnout effect in some odd-year elections but not others, admitting that “may present a challenge to the theory that increased complexity [from RCV] will have a marginal negative effect on voter turnout.” But he tried to wallpaper over that contradiction by blaming it on an unlikely source -- bad election administration. McDaniels wrote, “This would suggest that the negative impact of RCV on voter participation may be alleviated by high quality election administration,” without presenting any data or even anecdotes to support such an unfounded theory. While competent election administration of any election, whether RCV or non-RCV, is crucially important, there is no credible research that supports the far-fetched notion that the quality of election administration has much of an impact on voter turnout in US elections, whether using RCV or otherwise. Upgrade to a $5 subscription The unvirtuous circle of academic research It is puzzling how McDaniel’s first study could have survived the peer review process for the Journal of Urban Affairs. The mistakes in McDaniel’s first study above should have been obvious to anyone with a basic understanding of ranked choice voting as well as elections in general, and elections in San Francisco specifically. It undermines faith in the credibility of the peer review process to think that a jury of peer political scientists did not catch the egregious errors and reject McDaniel’s sloppy research and paper. And it remains a black mark on political science that this thoroughly discredited study has been cited dozens of times by other researchers. Indeed, in our research paper it became apparent that many political scientists cite each other’s flawed research to pad their list of citations and to legitimize their own flawed research, creating an unvirtuous circle of political science. More broadly, McDaniel’s voter turnout studies, like other studies evaluating RCV’s impact on turnout, lacked a recognition that no credible opinion or research can claim that RCV increases voter turnout merely because so many voters are excited to vote for their favorite candidates instead of “lesser evil” candidates without worrying about spoilers. Instead, with respect to turnout, the advantage of RCV has always been that, in most places where it has been used, it has eliminated a pre-November primary or post-November runoff, which usually saw about half the turnout of the November general election. This is especially true during even years when there are state and federal elections on the ballot which substantially drive turnout more than local contests. Any study that does not adequately account for this non-November primary/runoff vs November general election dynamic, or odd year vs even year election factors, is simply not credible. Both of McDaniel’s studies largely failed on those grounds. Steven Hill and Paul Haughey Share Upgrade to a $5 subscription Thanks for reading DemocracySOS…your digital portal for the pro-democracy movement. Subscribe for only $5 per month to receive full benefits and to support our work. Subscribe
5 Reasons Why Some Gamers Swear By Sennheiser Headphones
Sennheiser headphones match premium listener profiles, have great spatial imaging, multiple open-back architecture options, and an optimized ergonomic design.
Kansas City health and faith leaders team up to help minimize Medicaid coverage loss
New work requirements and twice-yearly eligibility checks are expected to cause millions of adults to lose Medicaid coverage. But community religious leaders and health advocates have been meeting every other week to plan and strategize about how to mitigate the damage.
Common antidepressant may ease long COVID’s crushing fatigue
A low-cost antidepressant may offer new hope for people struggling with long COVID fatigue. In a randomized clinical trial involving 399 adults, fluvoxamine significantly reduced fatigue and improved quality of life compared with a placebo, making it one of the first medications to show meaningful benefits for this disabling condition.
Faced with inadequate US healthcare, Black women fly to South Korea: ‘It could save your life’
Black women who feel minimized or dismissed in the US are traveling thousands of miles for South Korea’s patient-first approach
Doing More With Less: How Counties Can Successfully Address Behavioral Health Crisis Response Needs
Join Bamboo Health for a practical discussion on strategies county health departments can use to maximize resources and improve care outcomes.
Less sleep = less health; Led Zeppelin in the OR; dangers of people-pleasing; plus other stories with Vanderbilt Health sources
Prevention interviewed Beth Malow, MD, Professor of Neurology and Pediatrics in the Vanderbilt Sleep Division, for a story about two randomized trials published in Annals of Internal Medicinethat found decreasing sleep by just 1.5 hours each night was linked with increases in body weight, waist circumference, and sedentary time in adults with elevated cardiometabolic risk. Yahoo Healthalso picked up the story. WTVF News Channel 5 reporter Nikki Hauser interviewed Ashish Shah, MD, Professor and Chair of Cardiac Surgery, for a new video podcast series called “Why Nashville” where she interviews interesting people doing interesting work about why they came to Nashville and how it is going. Among the revelations: his go-to OR music includes Led Zeppelin and AC/DC. Everyday Health interviewed Aaron Brinen, PsyD, Assistant Professor of Psychiatry and Behavioral Sciences, for a story about the TikTok trend that encourages women to speak up about their concerns or they’ll develop an autoimmune disease. Overall, people suggest that suppressing feelings of anger, minimizing your own needs, or people-pleasing raises your risk. Telemundo Nashville broadcast a story on cyclosporiasis that quotes both William Schaffner, MD, professor of Preventive Medicine, and Juan C. Salazar, MD, MPH, chair of the Department of Pediatrics and system Pediatrician-in-Chief for Monroe Carell Jr. Children’s Hospital at Vanderbilt. Schaffner also spoke to WKRN News 2 about measles and The Cutabout shingles and long distance running. WREG (Memphis) and others picked up the measles story as well. CNN reporter Deidre McPhillips interviewed John Trahanas, MD, Assistant Professor of Cardiac Surgery, and Director of Thoracic Aortic Surgery, for a story about aortic dissection in last week’s death of U.S. Sen. Lindsey Graham. The Nashville Post published a story by freelance reporter Leah Hunter on robotic surgery, including a patient story and numerous quotes from Sekhar Padmanabhan, MD, Assistant Professor of Surgery in the Division of Surgical Oncology.
Google preps letting you customize Gemini voices by Speed, Energy, and more
After releasing two new options after I/O, Google might soon let you customize Gemini voice across four parameters.
PPG introduces PPG AEROVIEW virtual aircraft painter for business, general aviation
Innovative digital tool enhances aircraft paint color selection, design experience PPG (NYSE: PPG) today announced the launch of the PPG AEROVIEW™ virtual aircraft painter, a digital tool designed to help business and general aviation customers explore and customize aircraft paint colors with precision and ease. This web-based tool provides an interactive platform where users can select from a variety of aircraft models and digitally apply colors from PPG’s comprehensive aerospace color library to visualize custom paint schemes in real time. The PPG AEROVIEW™ virtual aircraft painter is a digital tool designed to help business and general aviation customers explore and customize aircraft paint colors with precision and ease. The PPG Aeroview virtual aircraft painter is designed to increase the visibility and accessibility of PPG’s aerospace coatings, particularly for business and general aviation markets. The tool provides a digital alternative to traditional physical color brochures
Google announces Gemma 4 optimized for the Pixel 10’s TPU
Google today announced Gemma 4 E2B for TPU that’s designed to run natively on the Pixel 10’s TPU. Gemma is Google's series...
Energy efficiency that delivers measurable business results
Lower costs, improve reliability and boost productivity with DTE Energy rebates, financing and customized energy efficiency solutions.
Danville Field Notes: BWXT employees earn data science certifications through Danville workforce development program
Plus: A local relief center plans for capital improvements, Pittsylvania pushes against an effort to minimize tree removal at anticipated micro-resort, and a music series begins in Danville’s River…
Kroenke Sports & Entertainment Partners with Summize to Transform Contract Operations Across its Global Portfolio
Summize, the AI-powered contract lifecycle management (CLM) platform purpose-built for in-house legal teams, today announced a partnership with Kroenke Sport...
How to Bring More Data Science to YouTube and Creator Media
I am constantly writing about the challenge facing agencies and brands when in comes to YouTube. Is it TV? Social video? Search? Commerce? Do you fund it from all of those respective budgets, and measure it using all their respective metrics? Sean Odlum, Chief Product Officer at Tinuiti, says it may not make sense to try and “bucket'“ YouTube. “You kinda gotta treat it as its own thing,” he said. “Years ago, we had debates [along the lines of] ‘what is this?’ Ultimately we decided, it’s YouTube. It is hard to categorize because it is so protean.” Which ultimately means that almost every part of a media department or marketing group will likely touch YouTube in some fashion. And that it probably needs its own sets of metrics and measurement tools. At Tinuiti, that need has led the agency to develop the YouTube Intelligence Suite, which aims to help brands optimize YouTube campaigns while using all the traditional marketing tools they are used to, such as MMMs. “I wouldn’t say there is a YouTube playbook,” Odlum said. “[For media planners] there is this vast bubbling ocean, so where do you start?’ A lot of brands and agencies struggle.” “You don’t want to just brute-force it—spray dollars everywhere and eventually learn. You want to start intelligently and then learn iteratively.” The problem, Odlum and his team have found, is that “brands have largely defaulted into demand generation campaigns because they’re easier to measure.” However, “you can really build your own content ecosystem around these trusted experts.” Check out the full interview here: Thanks for reading Next in Media! Subscribe for free to receive new posts and support my work. Subscribe
AHA itemizes ‘immediately addressable’ aspects of affordability
The American Hospital Association is banging the drum on healthcare affordability.
NAVER D2SF Invests in 23i, a Virtual Entertainment Startup
NAVER D2SF, the corporate venture capital arm of NAVER, has made a new investment in 23i (CEO, Hyungmin Kim), a virtual entertainment startup. As the global virtual entertainment market continues to grow rapidly, particularly in Korea and Japan, NAVER D2SF decided to invest in the team based on its ability to create expanded entertainment IP through strong content production capabilities and an in-house technology pipeline designed to maximize the strengths of virtual artists.
Joint Society Editorial Calls For Science-Based Approach to CV Health Equity
A joint editorial on behalf of the ACC, American Heart Association, European Society of Cardiology and World Heart Federation calls for a new era of equity-centered cardiovascular care designed to redefine prevention, optimize care delivery and ensure that all patients worldwide benefit equally from the promise of modern cardiovascular medicine.
Yankees Potential Trade Partner: Detroit Tigers
Would the likes of Skubal or Mize make sense for the Yankees?
The dangers behind health 'maxxing'
"Maxxing" is a way of promoting extreme ways to optimize physical and mental health.
You can now customize Siri's pace and expressivity in the latest iOS 27 beta
The new controls let you control how quickly Siri speaks and expressive its voice is.
A toxicologist's guide to reducing your exposure to everyday chemicals
There’s no such thing as a "chemical-free" life, but some simple steps can help you minimize exposures to daily chemicals.
Small Business Administration to help USDA sort 'lawfare' reports
John Rich says he’ll publicize cases of farmers being ‘shoved around’ The Small Business Administration agreed to help the USDA investigate complaints from farmers and ranchers who allege being victimized […]
Three Under-the-Radar Trade Targets for Philadelphia 76ers
To optimize a star-studded core, the Philadelphia 76ers must prioritize low-usage role players. These three players offer the chemistry and financial flexibility necessary for a deep postseason run.
SoFi (SOFI) Launches AI Investing And Small Business Loans In Product Push
SoFi Technologies (NasdaqGS:SOFI) has launched Composer by SoFi, an AI-powered investing platform designed to help members build and automate customized investment strategies. The company has also introduced SoFi Small Business Loans, a digital-first lending product aimed at giving entrepreneurs faster access to capital with no fees. These product rollouts expand SoFi's presence in AI-driven investing tools and small business lending within its broader financial services platform. SoFi...
Apple’s Strategy To Minimize iPhone 18 Pro Price Rise
As memory costs push the iPhone 18 Pro retail price upward, Apple can rely on services such as online backups and connected accessories to prevent premium users from moving to Android.
From Smoker to Advocate: A Powerful Lung Health Journey
For me, every breath today is a reminder. A reminder of where I’ve been, of what I’ve been given and of what’s at stake.
Treat Your Health Like A Private Equity Firm For Better Leadership
Disciplined investors have a specific way of evaluating and improving assets. Here's how executives can use that same lens to optimize their health and leadership.
Anthropic releases Claude Science, a product aimed at researchers, the pharma industry
Anthropic released Claude Science, an application that optimizes its large language model for scientists and, especially, those doing research at pharma companies.
Scientists say creatine may help fight depression
Creatine is best known as a muscle-building supplement, but scientists are now investigating whether it could also help treat depression by boosting the brain's energy supply. A new review examined five randomized clinical trials involving 238 participants and found mixed results. Two studies, both involving women with major depressive disorder, reported that adding creatine to standard treatment improved symptoms, while three others found no meaningful benefit.
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, demonstrated a statistically significant and clinically meaningful improvement in bone health in children (2 to
MAI-Code-1-Flash for Copilot Business and Copilot Enterprise
MAI-Code-1-Flash, Microsoft AI’s in-house coding model, is now generally available for GitHub Copilot Business and Copilot Enterprise, building on its recent expansion across Copilot surfaces. Purpose-built for coding and optimized…
AI designs the ideal burger for taste, health, and planet
Stanford researchers developed an AI tool that creates novel burger recipes optimized for individual preferences. The implications for science go well beyond food.
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
These Churches Are Putting Family Before Politics
Close to 70 percent of Black children in America are born to unmarried parents. Nearly half live with a single mother. Both figures are significantly higher than the national average and reflect the steep decline in marriage among African Americans since the 1960s.
To age better, we need to rethink health itself
Challenging conventional thinking has historically brought new ways to maximize health and improve quality of life while ageing. Here's what's needed now.
New York Yankees @ Detroit Tigers: Carlos Rodón vs. Casey Mize
Rodón looks to end this brief three-game skid and set up a Wednesday rubber game.
Priorities for Military Health System: ‘Our mission is readiness’
Keith Bass, assistant secretary of war for health affairs, outlines his strategic priorities for the Military Health System, with funding and staffing at the top of the list to optimize warfighter readiness.
Valve's Steam Machine ships June 29 for $1,049, but you probably won't be able to buy one yet
Valve says it's using a randomized purchase queue to make the experience "less frustrating and more fair."
France restricts public drinking and outdoor sports as heat wave bakes parts of Europe
The Eiffel Tower and other Paris venues set up misting stations to cool crowds, among a raft of measures introduced by authorities to minimize risks. Tourists in Rome dunked in fountains. Spain’s Basque Country canceled some sports and cultural events.
A Big Change Is Coming to Roku TVs
A big transformations are underway across the Roku TVs home screen as leading manufacturers, including TCL, begin implementing standardized home screen interfaces on their devices. This shift replaces the previous customized designs that each brand had developed independently with the uniform Roku platform experience. The result is a more consistent visual presentation that emphasizes the […]